Cargando…
Rapalink-1 Increased Infarct Size in Early Cerebral Ischemia–Reperfusion With Increased Blood–Brain Barrier Disruption
It has been reported that the mechanistic target of rapamycin (mTOR) pathway is involved in cerebral ischemia–reperfusion injury. One of the important pathological changes during reperfusion after cerebral ischemia is disruption of blood–brain barrier (BBB). Rapamycin, a first-generation mTOR inhibi...
Autores principales: | Chi, Oak Z., Liu, Xia, Cofano, Sean, Patel, Nikhil, Jacinto, Estela, Weiss, Harvey R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329705/ https://www.ncbi.nlm.nih.gov/pubmed/34354602 http://dx.doi.org/10.3389/fphys.2021.706528 |
Ejemplares similares
-
Commentary: Rapalink-1 Increased Infarct Size in Early Cerebral Ischemia–Reperfusion With Increased Blood–Brain Barrier Disruption
por: Beard, Daniel J., et al.
Publicado: (2021) -
Leucine Reduced Blood–Brain Barrier Disruption and Infarct Size in Early Cerebral Ischemia-Reperfusion
por: Chi, Oak Z., et al.
Publicado: (2023) -
Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
por: La Manna, Federico, et al.
Publicado: (2020) -
Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity
por: La Manna, Federico, et al.
Publicado: (2021) -
Increased Cell–Cell Coupling Increases Infarct Size and Does not Decrease Incidence of Ventricular Tachycardia in Mice
por: Prestia, Kevin A., et al.
Publicado: (2011)